The Grünenthal Group and Amura Therapeutics have entered into a collaboration for the development of protease inhibitors focused on cathepsin inhibitors to treat pain and inflammation. With advanced lead compounds generated from Amura, Grünenthal will develop small molecule drugs and assume responsibility for further R&D.
Grünenthal has exclusive rights for worldwide clinical development, manufacturing and commercialization of potential products arising from the collaboration. Grünenthal is responsible for costs and has made an undisclosed upfront payment, and will make further milestone payments.
“We are excited about this collaboration with Amura Therapeutics. Our expertise, strength and innovative power in developing therapies for patients suffering from pain and inflammatory diseases hopefully will help these patients in the future as these are still areas of unmet medical need,” said Dr. Klaus-Dieter Langner, executive vice president and chief operating officer of Grünenthal Innovation.
Dr. David Brown, chairman of Amura, said, “We are delighted to have entered into this exciting collaboration with Grünenthal. This agreement provides confirmation of the scientific and commercial validity of Amura’s novel AMcore platform and we look forward to a fruitful partnership with Grünenthal and developing new medicines in an area of unmet medical need.”